Neoadjuvant Cemiplimab Promising for Resectable Liver Cancer Neoadjuvant Cemiplimab Promising for Resectable Liver Cancer

Neoadjuvant cemiplimab induced pathological responses in one third of patients with resectable hepatocellular carcinoma in an ongoing phase 2 trial.Reuters Health Information
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news